Skip to main content

Peer Review reports

From: CKAP2L, a crucial target of miR-326, promotes prostate cancer progression

Original Submission
15 Sep 2021 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
15 Oct 2021 Reviewed Reviewer Report
17 Oct 2021 Reviewed Reviewer Report
14 Nov 2021 Author responded Author comments - Guochang Bao
Resubmission - Version 4
14 Nov 2021 Submitted Manuscript version 4
9 Dec 2021 Author responded Author comments - Guochang Bao
Resubmission - Version 5
9 Dec 2021 Submitted Manuscript version 5
28 Dec 2021 Author responded Author comments - Guochang Bao
Resubmission - Version 6
28 Dec 2021 Submitted Manuscript version 6
11 Mar 2022 Reviewed Reviewer Report
21 Mar 2022 Reviewed Reviewer Report
2 Apr 2022 Author responded Author comments - Guochang Bao
Resubmission - Version 7
2 Apr 2022 Submitted Manuscript version 7
4 Apr 2022 Author responded Author comments - Guochang Bao
Resubmission - Version 8
4 Apr 2022 Submitted Manuscript version 8
5 Apr 2022 Author responded Author comments - Guochang Bao
Resubmission - Version 9
5 Apr 2022 Submitted Manuscript version 9
10 Apr 2022 Reviewed Reviewer Report
15 Apr 2022 Reviewed Reviewer Report
3 May 2022 Author responded Author comments - Guochang Bao
Resubmission - Version 10
3 May 2022 Submitted Manuscript version 10
5 May 2022 Reviewed Reviewer Report
8 May 2022 Reviewed Reviewer Report
22 May 2022 Author responded Author comments - Guochang Bao
Resubmission - Version 11
22 May 2022 Submitted Manuscript version 11
25 May 2022 Reviewed Reviewer Report
Resubmission - Version 12
Submitted Manuscript version 12
Publishing
6 Jun 2022 Editorially accepted
17 Jun 2022 Article published 10.1186/s12885-022-09762-3

You can find further information about peer review here.

Back to article page